KYNB
KYNB clinical trials: KYNTRA BIO, INC.
Every trial on ClinicalTrials.gov where KYNTRA BIO, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 62
- Trials linked
- 41
- As lead sponsor
- 21
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
KYNB on the catalyst calendar · KYNB registry changes
- Primary completion Mar 31, 2028Sponsor estimatePhase 2NCT06842498A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)Kyntra Bio · Metastatic Castration-Resistant Prostate CancerRecruitingKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2030Sponsor estimatePhase 3NCT07722988A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic...Kyntra Bio · Myelodysplastic SyndromesNot yet recruitingKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 11, 2024ActualPhase 3NCT03941093Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus...Kyntra Bio · Pancreatic Cancer Non-resectableCompletedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 20, 2023ActualPhase 3NCT03955146Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Kyntra Bio · Idiopathic Pulmonary FibrosisTerminatedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 4, 2023ActualPhase 3NCT04419558Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Kyntra Bio · Idiopathic Pulmonary FibrosisTerminatedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 12, 2023ActualPhase 3NCT04632940Phase 3 Trial of Pamrevlumab or Placebo in Combination With Systemic Corticosteroids in Participants With Ambulatory DMDKyntra Bio · Duchenne Muscular DystrophyTerminatedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 7, 2020ActualPhase 2NCT02606136Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)Kyntra Bio · Duchenne Muscular DystrophyTerminatedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 9, 2023ActualPhase 3NCT03263091Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood...Kyntra Bio · Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)TerminatedKYNBLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 13, 2023ActualPhase 3NCT04371666Phase 3 Trial of Pamrevlumab or Placebo With Systemic Corticosteroids in Participants With Non-ambulatory Duchenne Muscular Dystrophy (DMD)Kyntra Bio · Duchenne Muscular DystrophyTerminatedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 1NCT00074698Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary FibrosisKyntra Bio · Idiopathic Pulmonary FibrosisCompletedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 3, 2023ActualPhase 3NCT05301517A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment...Kyntra Bio · Chemotherapy Induced AnemiaCompletedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 11, 2023ActualPhase 2/Phase 3NCT03303066Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)Kyntra Bio · AnemiaCompletedKYNBLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2021ActualPhase 1/Phase 2NCT02210559A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic CancerKyntra Bio · Pancreatic Cancer (Unresectable)CompletedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2021ActualPhase 3NCT04410198Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in...Kyntra Bio · Anemia Associated With End Stage Renal Disease (ESRD)CompletedKYNBLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 22, 2021ActualPhase 2NCT04432298Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 DiseaseKyntra Bio · COVID-19TerminatedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 9, 2021ActualPhase 3NCT04484857Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis ParticipantsKyntra Bio · Anemia Associated With End Stage Renal DiseaseCompletedKYNBLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 23, 2022ActualPhase 3NCT04621331Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKDKyntra Bio · Anemia Associated With Chronic Kidney DiseaseWithdrawnKYNBLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 26, 2021ActualPhase 2NCT04076943Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced AnemiaKyntra Bio · Chemotherapy Induced AnemiaCompletedKYNBLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 19, 2021ActualPhase 4NCT04059913Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With...Kyntra Bio · CKD Anemia in Dialysis ParticipantsCompletedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 13, 2012ActualPhase 2NCT01244763Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With AnemiaKyntra Bio · Chronic Kidney DiseaseCompletedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2012ActualPhase 2NCT01147666Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance HemodialysisKyntra Bio · End Stage Renal DiseaseCompletedKYNBLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 21, 2010ActualPhase 2NCT00761657Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring DialysisKyntra Bio · Chronic Kidney DiseaseCompletedKYNBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 19, 2018ActualPhase 3NCT02273726Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable DialysisKyntra Bio · CKD Anemia in Stable Dialysis PatientsCompletedKYNBLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 21, 2018ActualPhase 3NCT02052310Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis...Kyntra Bio · Anemia in Incident Dialysis PatientsCompletedKYNBLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 24, 2018ActualPhase 3NCT01750190A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving DialysisKyntra Bio · CKD AnemiaCompletedKYNBLeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 37 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner